The following information is intended as a resource for journalists only and was factually correct at the time it was issued.

Follow AbbVie UK

Tags

Latest news

AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) accepted for use within NHS Scotland

Press releases   •   Nov 16, 2017 00:01 GMT

Scottish Medicines Consortium accepts MAVIRET® for the treatment of adults in Scotland with chronic hepatitis C virus (HCV) infection

MPs back call for Government commitment to eliminate hepatitis C by 2030

AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) recommended for use within NHS Wales

Press releases   •   Oct 20, 2017 00:01 BST

All Wales Medicines Strategy Group recommends MAVIRET® for the treatment of adults in Wales with chronic hepatitis C virus (HCV) infection

Health leaders and politicians call for hepatitis C elimination strategy in Northern Ireland

Press releases   •   Oct 17, 2017 00:01 BST

Elected Members of the Legislative Assembly and patient group representatives will meet with leading clinicians and service providers today to discuss the need for a region-wide strategy for the elimination of hepatitis C in Northern Ireland

NICE recommends access to AbbVie’s VENCLYXTO®▼ (venetoclax) to treat most common form of adult leukaemia in England via Cancer Drugs Fund

Press releases   •   Oct 05, 2017 00:01 BST

Today the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending that AbbVie’s VENCLYXTO® (venetoclax) is made available to NHS patients with difficult-to-treat types of chronic lymphocytic leukaemia (CLL) via the Cancer Drugs Fund (CDF), providing conditions of the managed access agreement are followed.

AbbVie’s HUMIRA® (adalimumab) Approved by European Commission to Treat Paediatric Patients with Chronic Non-infectious Anterior Uveitis

Press releases   •   Sep 11, 2017 00:01 BST

Decision marks AbbVie’s HUMIRA® (adalimumab) as the only approved biologic treatment option in the European Union for paediatric patients from 2 years of age with chronic non-infectious anterior uveitis who have had inadequate response to conventional therapy

The Lancet Infectious Diseases publishes Phase 3 data showing 99 percent of adults with chronic hepatitis C infection and compensated cirrhosis achieved virologic cure with AbbVie’s glecaprevir/pibrentasvir

The Lancet Infectious Diseases publishes Phase 3 data showing 99 percent of adults with chronic hepatitis C infection and compensated cirrhosis achieved virologic cure with AbbVie’s glecaprevir/pibrentasvir

Press releases   •   Aug 16, 2017 00:01 BST

AbbVie, a global biopharmaceutical company, today announced The Lancet Infectious Diseases has published results from the Phase 3, single arm, open label, multicentre EXPEDITION-1 trial evaluating glecaprevir/pibrentasvir in chronic hepatitis C infected adult patients with genotypes 1, 2, 4, 5 or 6 and compensated cirrhosis.

Scotland first in the UK to make VENCLYXTO®▼ (venetoclax) routinely available for patients with most common form of adult leukaemia

Press releases   •   Aug 07, 2017 00:01 BST

Scottish Medicines Consortium accepts AbbVie’s venetoclax for routine prescribing across NHS Scotland, offering a new therapy option for patients with certain types of difficult-to-treat chronic lymphocytic Leukemia (CLL).

European Commission Grants AbbVie’s MAVIRET® (glecaprevir/pibrentasvir) Marketing Authorisation for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

Press releases   •   Jul 28, 2017 00:01 BST

MAVIRET is a new 8-week, pan-genotypic treatment for adult hepatitis C patients without cirrhosis and who are new to treatment

WORLD HEPATITIS DAY: London Assembly and health experts to agree priority actions needed to eliminate hepatitis C

Press releases   •   Jul 28, 2017 00:01 BST

Representatives from the London Assembly and local authorities in the Capital are set to meet with third sector and public health representatives in a roundtable meeting hosted by biopharmaceutical company, AbbVie, on World Hepatitis Day.

Experts Call for New focus on Value in NHS and Scaling up of Best Practice

Experts Call for New focus on Value in NHS and Scaling up of Best Practice

Press releases   •   Jul 19, 2017 00:01 BST

New report warns the NHS must reconsider its approach to value if it is to meet its productivity and efficiency saving targets and secure sustainability

2016 disclosure of AbbVie UK ‘Transfers of value’ to healthcare professionals and organisations

2016 disclosure of AbbVie UK ‘Transfers of value’ to healthcare professionals and organisations

Press releases   •   Jun 30, 2017 00:01 BST

Disclosure UK’, the central UK database for pharmaceutical industry transparency reporting, released its second full year of data on 30th June 2017.

Local health experts and MSPs call for focus on eliminating hepatitis C in Scotland

Press releases   •   Jun 27, 2017 00:01 BST

Local health experts and Members of the Scottish Parliament (MSPs) are meeting in Edinburgh to discuss what needs to be done to eliminate hepatitis C in Scotland by 2030

AbbVie Employees Donate more than 26,000 Hours in One Week to Communities Around the World

Press releases   •   Jun 26, 2017 00:01 BST

AbbVie UK joins colleagues around the world to make a difference in the lives of the underserved. More than 6,000 AbbVie employees in more than 50 countries will volunteer more than 26,000 service hours to make a difference in local communities during AbbVie’s Week of Possibilities.

AbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)

Press releases   •   Jun 23, 2017 00:01 BST

If approved, MAVIRET™ will provide a shorter, 8-week, pan-genotypic (GT1-6), once-daily option for the majority of people living with the hepatitis C virus (HCV)

AbbVie Appoints New General Manager in U.K.

AbbVie Appoints New General Manager in U.K.

Press releases   •   Jun 19, 2017 00:01 BST

Jérôme Bouyer has been appointed General Manager, AbbVie U.K.

Early Access to Medicines Scheme (EAMS) Granted to AbbVie’s Investigational Pan- genotypic Regimen for Chronic Hepatitis C – the First EAMS in HCV

Press releases   •   May 10, 2017 00:01 BST

AbbVie’s glecaprevir/pibrentasvir (G/P) is an investigational, pan-genotypic, ribavirin-free regimen being evaluated by the European Medicine’s Agency as a cure for hepatitis C virus (HCV) infection in patients across all genotypes (GT)

“We all have a part to play in making sure the NHS can meet the challenges it faces” says Alan Milburn

“We all have a part to play in making sure the NHS can meet the challenges it faces” says Alan Milburn

Press releases   •   May 04, 2017 00:01 BST

AbbVie’s new Live:Lab programme launches today and aims to improve the nation’s health through addressing the ‘Fear of Finding Out’ - focusing on prevention